Research programme: protein kinase inhibitors - AbbVie

Drug Profile

Research programme: protein kinase inhibitors - AbbVie

Alternative Names: A 1467729; A-443654; A-947864

Latest Information Update: 07 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Heterocyclic bicyclo compounds; Indazoles; Pyridines; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Checkpoint kinase 1 inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase inhibitors; Epidermal growth factor receptor antagonists; Insulin-like growth factor-I receptor antagonists; Janus kinase-2 inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Mantle cell lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 31 Mar 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top